Evolving Targets for Risk Reduction in Diabetes

Gregory M. Caputo, Joel B. Braunstein, Roger S. Blumenthal

Research output: Contribution to journalReview articlepeer-review

Abstract

Recent evidence shows that target low-density lipoprotein cholesterol should be less than 100 mg/dl in patients with diabetes, and that even those with initially low levels benefit from pharmacologic therapy. Recent studies document that blood pressures lower than the previous target of 140/90 mmHg are beneficial, in addition to providing observational evidence against a lower threshold of benefit. Evidence that addresses the effect of blood glucose on macrovascular disease risk in patients with diabetes is reviewed. Finally, recommendations are made regarding systematic changes in healthcare delivery that will facilitate risk reduction strategies in diabetes.

Original languageEnglish (US)
Pages (from-to)125-128
Number of pages4
JournalClinical Cardiology
Volume27
Issue number3
DOIs
StatePublished - Mar 2004

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Evolving Targets for Risk Reduction in Diabetes'. Together they form a unique fingerprint.

Cite this